在中枢神经系统中,prolyl氧酶域抑制剂的调节和保护作用
Konstantinos Matheoudakis1, John J O'Connor1
1UCD School of Biomolecular & Biomedical Science, UCD Conway Institute of Biomolecular & Biomedical Research, University College Dublin, Belfield, Dublin, Ireland.
Advances in pharmacology (San Diego, Calif.)
|February 10, 2025
概括
酸酶域抑制剂 (PHDIs) 通过激活缺氧诱导因子 (HIFs) 来提供神经保护. 这篇评论探讨了它们对神经系统疾病 (如中风和帕金森病) 的治疗潜力.
科学领域:
- 神经科学是一个神经科学.
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 氧气对哺乳动物大脑功能至关重要;低氧会触发适应性反应.
- 低氧诱导因子 (HIF) 是在低氧期间激活的关键转录因子.
- 酸酶域蛋白 (PHDs) 调节在正常状态下HIF的稳定性.
研究的目的:
- 审查PHD抑制剂 (PHDIs) 在神经疾病中的治疗潜力.
- 探索PHDIs在中枢神经系统疾病中的神经保护益处和限制.
- 检查PHDI对中枢神经系统功能的HIF激活的影响.
主要方法:
- 关于PHDI和神经疾病研究的文献综述.
- 对PHDI的作用机制的分析.
- 在中枢神经系统中探索HIF通路调制.
主要成果:
- PHDs激活HIFs,这些HIFs通常被PHDs在normoxia下降解.
- 在中风,帕金森病和ALS等疾病中,PHDI显示出潜在的神经保护益处.
- 由PHDIs激活HIF可以调节神经传递和突触可塑性.
结论:
- PHDI代表了低氧相关神经系统疾病的有前途的治疗策略.
- 需要进一步的研究才能充分了解PHDIs的好处和局限性.
- 由PHDI诱导的HIF激活可能为认知增强提供新的治疗途径.
相关概念视频
Drugs Affecting Neurotransmitter Synthesis
1.2K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
1.2K
Indirect-Acting Cholinergic Agonists: Mechanism of Action
1.5K
Indirect-acting cholinergic agonists work by interacting with an enzyme called acetylcholinesterase (AChE) in the synaptic cleft. They can be reversible or irreversible inhibitors and have different effects on the enzyme.
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex,...
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex,...
1.5K
Ligand-Gated Ion Channel Receptor: Gating Mechanism
2.1K
Ligand-gated ion channels are transmembrane proteins that play a vital role in intercellular communication and functions of the nervous system. They allow the influx of ions across the membrane once the neurotransmitter binds, allowing the subsequent transmission of electrical excitation across the neurons. Other ligand-gated ion channels, like the γ-aminobutyric acid (GABA) receptor, permit anions like chloride into the cells on the binding of the GABA molecule. Their entry into the cell...
2.1K
Indirect-Acting Cholinergic Agonists: Pharmacological Actions
608
Indirect-acting cholinergic agonists, also known as anticholinesterases, exert their pharmacological effects by enhancing cholinergic transmission in various body parts, including the neuromuscular junction, autonomic cholinergic synapses, and the brain.
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
608
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
216
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
216
Adrenergic Agonists: Indirect-Acting Agents
1.5K
Indirect-acting adrenergic agonists potentiate the effects of endogenous catecholamines through different mechanisms without directly binding to adrenoceptors.
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...
1.5K


